Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Gynecol Endocrinol ; 36(4): 285-288, 2020 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31711322

RESUMEN

Vitamin K2 (vit K2) belongs to a large group of fat-soluble compounds whose formulation is MK (menaquinone) (MK-2 to MK-14), that seem to be involved in different biological functions. In particular, vit K2 has been recently recognized as efficacious and safe in treatment of bone loss, as it contributes to structural integrity of osteocalcin (OC), the major non-collagenous protein typically found in bone matrix. Several studies proved low vit K2 intake is linked to bone loss and to increased fracture risk in both sexes. Nowadays, vit K2 supplementation is considered a significant manner to enhance the association of calcium and vitamin D whose role on bone health is largely recognized. On the other hand, vit K2 may be used alone or with other drugs to preserve bone quality/strength from skeletal degradation after menopause and/or in patients affected by secondary osteoporosis. In this paper, we review the most recent data about vit K2 on skeleton.


Asunto(s)
Huesos/efectos de los fármacos , Huesos/metabolismo , Vitamina K 2/farmacología , Densidad Ósea/efectos de los fármacos , Densidad Ósea/fisiología , Enfermedades Óseas Metabólicas/epidemiología , Enfermedades Óseas Metabólicas/etiología , Enfermedades Óseas Metabólicas/terapia , Calcio/sangre , Suplementos Dietéticos , Femenino , Humanos , Masculino , Osteoporosis/epidemiología , Osteoporosis/etiología , Osteoporosis/prevención & control , Osteoporosis Posmenopáusica/epidemiología , Osteoporosis Posmenopáusica/etiología , Osteoporosis Posmenopáusica/prevención & control , Factores de Riesgo , Vitamina D/sangre , Vitamina K 2/sangre
2.
Gynecol Endocrinol ; 36(3): 185-189, 2020 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-32093515

RESUMEN

The scientific interest and the number of papers dealing with vitamin D supplementation has greatly grown in the last decades. Unfortunately, expert consensus on many clinical aspects of this topic is still lacking. In addition, data coming from recent clinical trials and meta-analyses seem to strongly put into doubt the real benefit of vitamin D supplementation, on both skeletal and extra-skeletal outcomes. This is further confusing since they seem to completely contradict the considerable body of evidence provided from previous epidemiological studies. This paper aims to analyze these new data in order to shed light onto the debated issues.


Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Diabetes Mellitus Tipo 2/prevención & control , Fracturas Óseas/prevención & control , Neoplasias/prevención & control , Deficiencia de Vitamina D/tratamiento farmacológico , Vitamina D/uso terapéutico , Vitaminas/uso terapéutico , Accidentes por Caídas/prevención & control , Suplementos Dietéticos , Humanos , Metaanálisis como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto
3.
Climacteric ; 22(3): 303-306, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30626218

RESUMEN

Nowadays, postmenopausal women are largely undertreated. Analysis of conflicting results among different studies suggests that hormone replacement therapy (HRT) can prevent osteoporosis and cardiovascular disease in symptomatic, early postmenopausal women. In fact, climacteric symptoms are related to an increased risk of chronic conditions, including hypertension and cardiovascular disease. Different scientific societies have pointed out that patient selection, timing of initiation, and the choice of the type and dose of HRT used are the major determinants of the ultimate effect of HRT on women's health and quality of life in selected women. HRT may prevent chronic conditions when started in symptomatic women before the age of 60 years or within 10 years of the onset of the menopause, taking into consideration the characteristics and risk profiles of each given woman. The bulk of scientific evidence from preclinical, clinical, epidemiological, and also randomized studies indicates that wisely selected HRT is generally useful and rarely dangerous. Following simple and well-established rules, HRT benefits outweigh all of the possible risks. Progestogen choice can make the difference in terms of cardiovascular disease benefits.


Asunto(s)
Enfermedad Crónica/prevención & control , Terapia de Reemplazo de Estrógeno , Posmenopausia/fisiología , Factores de Edad , Enfermedades Cardiovasculares/prevención & control , Terapia de Reemplazo de Estrógeno/métodos , Femenino , Humanos , Persona de Mediana Edad , Osteoporosis Posmenopáusica/prevención & control , Progestinas/administración & dosificación , Calidad de Vida
4.
Climacteric ; 20(4): 306-312, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28453310

RESUMEN

Menopausal disorders may include shorter-term symptoms, such as hot flushes and night sweats (vasomotor symptoms, VMS) and longer-term chronic conditions such as cardiovascular disease (CVD), osteoporosis, and cognitive impairment. Initially, no clear link between the shorter-term symptoms and longer-term chronic conditions was evident and these disorders seemed to occur independently from each other. However, there is a growing body of evidence demonstrating that VMS may be a biomarker for chronic disease. In this review, the association between VMS and a range of chronic postmenopausal conditions including CVD, osteoporosis, and cognitive decline is discussed. Prevention of CVD in women, as for men, should be started early, and effective management of chronic disease in postmenopausal women has to start with the awareness that VMS during menopause are harbingers of things to come and should be treated accordingly.


Asunto(s)
Biomarcadores , Enfermedades Cardiovasculares/epidemiología , Enfermedad Crónica/epidemiología , Sofocos/epidemiología , Menopausia/fisiología , Sistema Vasomotor/fisiopatología , Adulto , Anciano , Densidad Ósea , Trastornos del Conocimiento/epidemiología , Estrógenos/deficiencia , Femenino , Sofocos/fisiopatología , Humanos , Persona de Mediana Edad , Osteoporosis Posmenopáusica/epidemiología , Factores de Riesgo , Sudoración/fisiología
5.
Gynecol Endocrinol ; 31(8): 590-4, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26036806

RESUMEN

Osteoporosis (OP) and cardiovascular diseases (CVD) are the most important causes of mortality and morbility in the elderly. Lots of studies showed a correlation between bone loss and cardiovascular risk mediated by the vascular calcification. The relationship between OP and CVD could be firstly explained by their common risk factors such as age, smoking, alcohol consumption, physical activity and menopause. However, other different hypotheses were proposed to clarify this link. Multiple factors, for example bone morphogenetic proteins, osteoprotegerin, receptor activator of nuclear factor κB ligand, parathyroid hormone, phosphate, oxidized lipids and vitamins D and K seemed to be involved in both conditions, indicating a possible common pathophysiologic mechanism. We review and discuss the available data describing this association. Further studies are necessary to better investigate similarities between OP and CVD.


Asunto(s)
Enfermedades Cardiovasculares/complicaciones , Osteoporosis/complicaciones , Proteínas Morfogenéticas Óseas/metabolismo , Enfermedades Cardiovasculares/metabolismo , Enfermedades Cardiovasculares/fisiopatología , Humanos , Osteoporosis/metabolismo , Osteoporosis/fisiopatología , Hormona Paratiroidea/metabolismo , Ligando RANK/metabolismo , Factores de Riesgo
7.
J Eur Acad Dermatol Venereol ; 26(11): 1364-71, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22011217

RESUMEN

BACKGROUND: Despite it is accepted that acne is mostly caused by an hyper-responsiveness of the pilo-sebaceous unit to normal circulating androgen hormones, in a few patients, especially women, acneic lesions can be associated with increased serum androgen levels (hyperandrogenism), of which polycystic ovary syndrome (PCOS) is the most common cause. In women with acne and proven PCOS therapy with estroprogestins (EPs) can be an excellent option. OBJECTIVE: The aim of the study was to assess the effects of two estroprogestins (EPs), ethinyl-estradiol (EE) 30 mcg/drospirenone (DRSP) 3 mg, and ethinyl-estradiol (EE) 30 mcg/chlormadinone acetate (CMA) 2 mg, both on increased serum androgen levels and on several skin parameters in women affected by mild to severe acne and polycystic ovary syndrome (PCOS). METHODS: Fifty-nine women were randomized to receive EE/DRSP (n = 32) or EE/CMA (n = 27) for six months. Evaluation of serum androgen levels, grading of acne and hirsutism (respectively with Pillsbury and Ferriman-Gallwey score) and non-invasive assessment of skin hydration, transepidermal water loss (TEWL) and skin homogeneity were performed at baseline, at 3 and 6 months (end of treatment). RESULTS: Both treatments were well tolerated and showed a significant improvement of skin and hormonal parameters, although EE/DRSP showed a more potent effect on acne and seborrhea. CONCLUSIONS: Estroprogestins represent an effective and safe treatment in women with acne and polycystic ovary syndrome (PCOS). Nevertheless, the combination EE 30 mcg/DRSP 3 mg appears to be a more potent therapeutic option.


Asunto(s)
Acné Vulgar/tratamiento farmacológico , Anticonceptivos Orales Combinados/uso terapéutico , Estrógenos/uso terapéutico , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Progestinas/uso terapéutico , Acné Vulgar/complicaciones , Adolescente , Adulto , Estrógenos/administración & dosificación , Femenino , Humanos , Síndrome del Ovario Poliquístico/complicaciones , Progestinas/administración & dosificación
8.
Minerva Ginecol ; 63(3): 305-14, 2011 Jun.
Artículo en Italiano | MEDLINE | ID: mdl-21654615

RESUMEN

Prevention of osteopenia/osteoporosis in postmenopausal patients can reduce fracture risk. In this view, the use of Selective Estrogen Receptor Modulators (SERMs) appear to be important in managing this condition. Bazedoxifene Acetate (BZA) is a third-generation SERM that showed to protect bone mass in postmenopausal women with osteopenia, and to reduce vertebral fracture risk in osteoporotic postmenopausal women; moreover, BZA decreased the non-vertebral fracture risk in a subgroup of patients at high-risk for fracture in comparison to placebo. BZA showed no stimulating effects on endometrium and breast. BZA can be a valid option in management of osteopenia/osteoporosis in postmenopause.


Asunto(s)
Indoles/uso terapéutico , Osteoporosis Posmenopáusica/prevención & control , Moduladores Selectivos de los Receptores de Estrógeno/uso terapéutico , Femenino , Humanos , Clorhidrato de Raloxifeno/uso terapéutico
9.
Minerva Ginecol ; 62(5): 483-95, 2010 Oct.
Artículo en Italiano | MEDLINE | ID: mdl-20938431

RESUMEN

Progestins are a group of different compounds sharing the ability to induce secretory changes on a endometrium pretreated with estrogen, while they are different in some abilities, for example the interaction with receptors other than progestin receptor, as androgenic or mineralocorticoid receptor. Some progestins have antiandrogenic properties and are used in treating hyperandrogenic manifestations (seborrhea, acne, hirsutism). The different clinical pharmacology of the various progestins is the basis for an individualized treatment in different clinical conditions. Key words.


Asunto(s)
Progestinas , Femenino , Humanos , Hiperandrogenismo/tratamiento farmacológico , Progesterona/fisiología , Progestinas/metabolismo , Progestinas/farmacología , Progestinas/uso terapéutico
10.
Minerva Ginecol ; 62(6): 509-13, 2010 Dec.
Artículo en Italiano | MEDLINE | ID: mdl-21079572

RESUMEN

AIM: evaluate the efficacy of an estroprogestin EP containing 20 mcg ethinilestradiol (EE) and 3 mg drospirenone (DRSP) in the treatment of hyperandrogenism. METHODS: In this study, twenty hyperandrogenic patients were treated with an EP containing EE 20 mcg and DRSP 3 mg in 24+4 regimen for three months. Skin evaluation was performed both quantitatively and qualitatively. RESULTS AND CONCLUSION: This EP combination showed, after a short-term treatment (three months) to decrease significantly seborrhea, acne, and circulating androgens (testosterone, deidroepiandrosterone sulphate, and androstenedione), while increased sex hormone binding globulin levels. Moreover, this EE 20 mcg/DRSP 3mg EP combination changed some parameters of skin quality, increasing corneometry (a parameter related to skin hydration), and reduced trans epidermal water loss (TEWL, a parameter related to skin evaporation), and erythema (a parameter related to skin inflammation). These results could be taken into account in individualizing the treatment of hyperandrogenic patients.


Asunto(s)
Androstenos/administración & dosificación , Estrógenos/administración & dosificación , Etinilestradiol/administración & dosificación , Hiperandrogenismo/tratamiento farmacológico , Antagonistas de Receptores de Mineralocorticoides/administración & dosificación , Norpregnenos , Administración Oral , Adolescente , Adulto , Combinación de Medicamentos , Femenino , Humanos , Hiperandrogenismo/diagnóstico , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento
11.
Eur J Obstet Gynecol Reprod Biol ; 250: 235-240, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32497923

RESUMEN

Polycystic Ovary Syndrome is a very complex syndrome, with typical hormonal and metabolic features. In adolescent girls, this condition shows particular characteristics which are in common with adult sign and symptoms, often making the diagnosis difficult. On the other side, treatment strategy aims to manage the different aspects of this syndrome, and is generally based on lifestyle/diet modifications possibly associated with use of estroprogestins, anti-androgens and insulin-sensitizing agents. In this article, we will briefly review both diagnosis and clinical approach to polycystic ovary syndrome in adolescence which still remain a matter of debate in view of the peculiar hormonal milieu of that critical period.


Asunto(s)
Resistencia a la Insulina , Metformina , Síndrome del Ovario Poliquístico , Adolescente , Adulto , Femenino , Humanos , Hipoglucemiantes , Insulina , Síndrome del Ovario Poliquístico/diagnóstico , Síndrome del Ovario Poliquístico/terapia
12.
Climacteric ; 12(6): 533-40, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19905905

RESUMEN

OBJECTIVES: To assess perception of sexuality and awareness of the impact of testosterone on sexual desire in a clinical sample of Italian women with surgical menopause. METHODS: In the present cross-sectional study, a structured interview on sexuality-related menopausal symptoms, attitudes towards sexuality and menopausal profile was administered to 568 women (age range 35-69 years) with bilateral oophorectomy with and without hysterectomy for benign conditions. RESULTS: The majority of women (58% yes; 36% most of the time) reported they were satisfied with their sexual life before surgical menopause. After oophorectomy, 79.3% noted the appearance/worsening of vaginal dryness, whereas the reduction of sexual desire was reported by 78.7%. Women with low sexual desire (n = 436) were significantly distressed (59.7%) and reported an impairment (24.8% yes/yes, very much) in the relationship with their partner. Sexual reactions of the partner reported by women included reduced sexual desire (17.8%), sexual dysfunction (5.1%) and fears of giving pain/lack of pleasure (28.3%). A high number of women (88.2%) would be willing to discuss sexual matters with their doctors and would consider therapeutic options. Only 36.8% were aware that a lack of testosterone might impact on sexual desire but 71% would like to know more about the role of testosterone. Hormone replacement therapy was used by 38.4% of the women. CONCLUSIONS: These data suggest that women experience significant vaginal dryness and low sexual desire and report a significant distress in the relationship with their partner after surgical menopause. Sexual counseling is mandatory in order to discuss potential therapeutic strategies, including testosterone use.


Asunto(s)
Menopausia , Ovariectomía/efectos adversos , Disfunciones Sexuales Fisiológicas/epidemiología , Testosterona/uso terapéutico , Adulto , Anciano , Estudios Transversales , Femenino , Humanos , Persona de Mediana Edad , Disfunciones Sexuales Fisiológicas/tratamiento farmacológico , Disfunciones Sexuales Fisiológicas/etiología , Disfunciones Sexuales Psicológicas/tratamiento farmacológico , Disfunciones Sexuales Psicológicas/epidemiología , Disfunciones Sexuales Psicológicas/psicología , Encuestas y Cuestionarios , Testosterona/fisiología , Enfermedades Vaginales/etiología
13.
Minerva Ginecol ; 61(5): 459-63, 2009 Oct.
Artículo en Italiano | MEDLINE | ID: mdl-19749678

RESUMEN

Progestogens are used in clinical practice in some conditions. Their effects depend on their chemical structure, pharmacokinetics, pharmacodynamics, with important differences among various progestogens. Generally, progestins are classified according to their parent molecule, of which often they keep some features. Derivatives of 19-nor-progesterone are characterized by high selectivity of action on progestin receptor. In particular, nomegestrol acetate (NomAc) shows an important progestational potency, neutral gluco-lipid profile, and antigonadotropic activity. It is used for treating menstrual cycle disorders and for hormone replacement therapy in menopause in association with an estrogen. In future, thanks to its antigonadotropic activity, NomAc will be used in estroprogestin combinations in fertile women, thus taking advantage of its tolerability profile and obtaining numerous non-contraceptive benefits as well.


Asunto(s)
Megestrol/farmacología , Norpregnadienos/farmacología , Disponibilidad Biológica , Enfermedades de la Mama/tratamiento farmacológico , Quimioterapia Combinada , Estradiol/administración & dosificación , Estradiol/análogos & derivados , Femenino , Terapia de Reemplazo de Hormonas , Humanos , Sistema Hipotálamo-Hipofisario/efectos de los fármacos , Inactivación Metabólica , Megestrol/efectos adversos , Megestrol/química , Megestrol/farmacocinética , Megestrol/uso terapéutico , Menopausia , Trastornos de la Menstruación/tratamiento farmacológico , Estructura Molecular , Norpregnadienos/efectos adversos , Norpregnadienos/química , Norpregnadienos/farmacocinética , Norpregnadienos/uso terapéutico , Inhibición de la Ovulación/efectos de los fármacos , Unión Proteica
14.
Minerva Ginecol ; 60(3): 239-43, 2008 Jun.
Artículo en Italiano | MEDLINE | ID: mdl-18547986

RESUMEN

AIM: This study evaluated hormonal and skin effects in hyperandrogenic women of an oral estroprogestin (EP) association containing ethynilestradiol 30 mcg plus drospirenone 3 mg. METHODS: Thirty two women with signs and symptoms of hyperandrogenism (seborrhea, acne, increased hair); hormonal assessment (follicle-stimulating hormone, [FSH]; luteinizing hormone, LH; 17-hydroxi-progesterone, 17OHP; androstenedione, A, testosterone, T; dehydroepiandrosterone sulfate, DHEAS; sex hormone binding globulin, [SHBG]; Free Androgen Index [FAI, Tx100/SHBG] was performed before the start of treatment, and after 3 and 6 months of administration of EP. The impact on seborrhea, acne, and hair pattern (Ferriman-Gallwey score) was assessed, and, by non-invasive technique, hydration, water transpiration, and homogeneity of the skin were evaluated. RESULTS: Treatment with this EP for 6 months decreased significantly circulating androgen levels (A, T, DHEAS) and FAI, and increased SHBG levels, also reducing seborrhea, acne and hirsutism. Moreover, EE/DRSP increased hydration and improved overall appearance of skin surface (homogeneity). CONCLUSION: Treatment with EE 30 mcg+DRSP 3 mg improves hormonal pattern and skin appearance in hyperandrogenic patients, potentially with subsequent, beneficial effects on quality of life of these women.


Asunto(s)
Androstenos/uso terapéutico , Dermatitis Seborreica/tratamiento farmacológico , Etinilestradiol/farmacología , Hiperandrogenismo/tratamiento farmacológico , Hiperandrogenismo/fisiopatología , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico , Norpregnenos/farmacología , Piel/efectos de los fármacos , Adolescente , Adulto , Combinación de Medicamentos , Etinilestradiol/administración & dosificación , Etinilestradiol/uso terapéutico , Femenino , Humanos , Hiperandrogenismo/diagnóstico , Norpregnenos/uso terapéutico , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
15.
Am J Clin Nutr ; 72(3): 780-3, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10966899

RESUMEN

BACKGROUND: An increase in total body water is common in normal pregnancy. It is thought to be an important mechanism of maternal adaptation to pregnancy. OBJECTIVE: The aim of the present study was to assess longitudinal changes in body water compartments in pregnant women and to correlate these measurements with the course of pregnancy. DESIGN: One hundred seventy-three pregnant women with apparently normal, single pregnancies participated in this longitudinal study. Anthropometric measurements and multifrequency bioelectrical impedance were performed during the first, second, and third trimesters of pregnancy. RESULTS: One hundred three of the women completed all of the measurements; 50 of the women had a normal pregnancy and 13 had gestational hypertension. Total body water, extracellular water, and intracellular water values in normal pregnancies showed a significant, progressive increase throughout pregnancy. In women with gestational hypertension, total body water, extracellular water, and intracellular water values showed an opposite trend, suggesting a lack of plasma volume expansion through fluid-retention mechanisms. CONCLUSIONS: Our results show that multifrequency bioelectrical impedance analysis can be used to monitor variations in body water compartments in normal pregnancy and detect gestational hypertension.


Asunto(s)
Hipertensión/fisiopatología , Complicaciones Cardiovasculares del Embarazo/fisiopatología , Adulto , Agua Corporal/metabolismo , Impedancia Eléctrica , Espacio Extracelular/metabolismo , Femenino , Humanos , Hipertensión/diagnóstico , Hipertensión/metabolismo , Líquido Intracelular/metabolismo , Estudios Longitudinales , Embarazo , Complicaciones Cardiovasculares del Embarazo/diagnóstico , Complicaciones Cardiovasculares del Embarazo/metabolismo , Valores de Referencia
16.
Psychoneuroendocrinology ; 25(7): 659-75, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-10938447

RESUMEN

We tested the hypothesis that changes in endogenous neuroactive steroids acting as positive allosteric modulators of gamma-aminobutyric acid (GABA)(A) receptors may be related to the menopause-associated mood alterations. The study sample consisted of twenty five drug-free menopausal women, 1-3 years since the onset of menopause, homogeneous for age and body mass index (BMI) and without personal history of psychiatric, metabolic or endocrine disorders. Depression and anxiety-related symptoms were assessed with the Zung Self-administered Depression Scale (ZSDS) and the Cornell's Dysthymia Rating Scale (CDRS). The cut-off value predicted by the ZSDS index defined two groups of women (asymptomatic [35.5+/-4.6, n=12] and symptomatic [60.8+/-7.9, n=13]), that were also significantly different according to the CDRS scores (10.6+/-3.4 and 31.5+/-12, respectively, P<0.05). Upon evaluation of the scores relative to the anxiety factor of the CDRS (items 11-15) the symptomatic, but not the asymptomatic, group showed a moderate level of anxiety. The plasma concentrations of several neuroactive steroids were measured, after extraction and HPLC purification, by radioimmunoassay with specific antisera. Only dehydroepiandrosterone and its metabolite 5alpha-androstane-3alpha,17betadiol (3alpha-ADIOL), a positive allosteric modulator of GABA(A) receptors, were significantly (P<0.05 and P<0.005) higher (+110% and +64%, respectively) in the asymptomatic group. A highly significant and negative correlation (r=-0.672, P=0.003) was found between the plasma 3alpha-ADIOL concentrations and the scores of the anxiety factor of the CDRS. These data suggest that endogenous 3alpha-ADIOL modulates the central GABAergic tone and that higher 3alpha-ADIOL concentrations could have a role in preventing the expression of anxiety in the asymptomatic women.


Asunto(s)
Ansiedad/fisiopatología , Climaterio/fisiología , Etiocolanolona/análogos & derivados , Receptores de GABA-A/fisiología , Ansiedad/psicología , Climaterio/psicología , Depresión/fisiopatología , Depresión/psicología , Etiocolanolona/sangre , Femenino , Humanos , Persona de Mediana Edad , Inventario de Personalidad
17.
Fertil Steril ; 71(3): 536-43, 1999 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-10065794

RESUMEN

OBJECTIVE: To assess uterine artery blood flow and endometrial thickness in postmenopausal patients receiving sequential hormone replacement therapy (HRT) at different phases of the treatment. DESIGN: Prospective controlled study. SETTING: Ultrasound and menopause units of the obstetrics and gynecology department of the University of Tor Vergata, Rome, Italy. PATIENT(S): Forty postmenopausal women were treated with cyclic sequential HRT (transdermal E2, 50 microg/d, days 1-21; and dydrogesterone, 10 mg/d, days 12-24). INTERVENTION(S): All patients underwent transvaginal color Doppler sonography in the estrogen (phase E) and progestogen (phase E/P) phases and after uterine bleeding when no hormone was administered (phase 0). MAIN OUTCOME MEASURE(S): Endometrial thickness; systolic, diastolic, and mean velocities; and pulsatility and resistance indices of the uterine arteries. RESULT(S): No statistically significant difference in endometrial thickness between phase E (6.5+/-1.6 mm) and phase E/P (6.0+/-1.7 mm) was observed. In phase 0, compared with phases E and E/P, a statistically significant decrease in endometrial thickness was found (4.1+/-1.2 mm). Doppler flow impedance parameters of uterine arteries during the different phases of the HRT cycle showed no differences between the phases considered. CONCLUSION(S): The decrease in endometrial thickness in phase 0 suggests a protective effect of our cyclic sequential regimen on the endometrium. Dydrogesterone does not interfere markedly with the vasodilatory effect of estrogen on uterine arteries.


Asunto(s)
Didrogesterona/farmacología , Estrógenos/farmacología , Terapia de Reemplazo de Hormonas , Congéneres de la Progesterona/farmacología , Útero/efectos de los fármacos , Útero/diagnóstico por imagen , Anciano , Didrogesterona/uso terapéutico , Endometrio/diagnóstico por imagen , Endometrio/efectos de los fármacos , Endometrio/patología , Estrógenos/uso terapéutico , Femenino , Humanos , Persona de Mediana Edad , Posmenopausia , Congéneres de la Progesterona/uso terapéutico , Estudios Prospectivos , Flujo Sanguíneo Regional , Ultrasonografía Doppler en Color , Útero/irrigación sanguínea
18.
Minerva Ginecol ; 56(4): 349-52, 2004 Aug.
Artículo en Italiano | MEDLINE | ID: mdl-15377983

RESUMEN

Urinary incontinence is a disease able to decrease the quality of life of affected women. It shows a prevalence of about 35% among adult women. Pharmacological treatment can be used when pelvic floor muscle training has failed or when it could be better to postpone or avoid surgery. Duloxetine, a selective serotonin and noradrenaline reuptake inhibitor (SNRI), can act effectively in treating stress urinary incontinence.


Asunto(s)
Inhibidores de Captación Adrenérgica/uso terapéutico , Tiofenos/uso terapéutico , Incontinencia Urinaria/tratamiento farmacológico , Clorhidrato de Duloxetina , Femenino , Humanos , Resultado del Tratamiento , Incontinencia Urinaria/diagnóstico
20.
J Food Prot ; 75(10): 1859-61, 2012 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23043838

RESUMEN

The aim of this study was to investigate the hygiene performance of a camel (Camelus dromedarius) slaughtering process as carried out with the traditional method in the Sahrawi refugee camps located in southwestern Algeria. The camel slaughtering process in this region differs significantly from that carried out in commercial abattoirs. Slaughtering is performed outdoors in desert areas, and dehiding of the carcass is approached via the dorsoventral route rather than the classic ventrodorsal route. Samples were taken from 10 camel carcasses from three different areas: the hide, the carcass meat immediately after dehiding, and the meat after final cutting. Enterobacteriaceae counts (EC) were enumerated employing conventional laboratory techniques. Carcass meat samples resulted in EC below the detection limit more frequently if the hide samples from the same carcass had also EC counts below the detection limit. Because of the low number of trials, the calculation of statistical significance of the results was not possible. Further experimental research is needed in order to validate the results presented in this study. The comparison of the microbiological hygiene performance between dorsal dehiding and traditional ventral dehiding of slaughtered animals could serve to validate the hypothesis of the potential positive impact of the dorsal dehiding method in carcass meat hygiene.


Asunto(s)
Camelus , Enterobacteriaceae/aislamiento & purificación , Eutanasia Animal/métodos , Contaminación de Alimentos/análisis , Manipulación de Alimentos/métodos , Carne/microbiología , Mataderos , Argelia , Animales , Camelus/microbiología , Recuento de Colonia Microbiana , Contaminación de Alimentos/prevención & control , Humanos , Higiene , Carne/normas , Medición de Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA